Repare Therapeutics Inc (RPTX) FinancialsRPTXFinancialRepare Therapeutics Inc

Evaluating the bottom line, Repare Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3.70%, while the net margin is 28.04%. These profitability ratios, combined with a Return on Equity (ROE) of -49.78%, provide a clear picture of how effectively RPTX converts its operational activities into shareholder value.

In the context of the broader market, RPTX competes directly with industry leaders such as MGNX and ADAG. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, RPTX's gross margin of 100.00% stands against MGNX's N/A and ADAG's 100.00%. Such benchmarking helps identify whether Repare Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Latest quarter: 2025/Q3. Revenue increased to $11.62M (flat YoY at ~0.00% change). Profitability weakened materially: Net income fell to $3.258M (-109.47% YoY) and EPS to $0.08 (-109.88% YoY). Gross margin reported at 100 (flat). Overall, the quarter shows no clear accelerating growth trend and worsening earnings versus last year, which does not provide a fundamental tailwind to justify a price meaningfully above the stated acquisition value.